Zoetis Inc. (NYSE:ZTS) Shares Sold by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC lowered its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 37.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,041 shares of the company's stock after selling 7,861 shares during the period. Bryn Mawr Capital Management LLC's holdings in Zoetis were worth $2,147,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Navigoe LLC purchased a new stake in shares of Zoetis during the fourth quarter valued at approximately $30,000. Cornerstone Planning Group LLC raised its holdings in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after buying an additional 88 shares during the last quarter. Murphy & Mullick Capital Management Corp bought a new stake in Zoetis during the 4th quarter valued at $44,000. Sound Income Strategies LLC boosted its position in Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares during the period. Finally, Bfsg LLC grew its holdings in Zoetis by 614.6% in the 1st quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after acquiring an additional 252 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Down 0.9%

Shares of Zoetis stock traded down $1.39 during trading on Thursday, hitting $150.16. 2,301,301 shares of the stock traded hands, compared to its average volume of 2,604,401. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. The stock's fifty day simple moving average is $161.24 and its 200 day simple moving average is $161.62. The firm has a market cap of $66.85 billion, a P/E ratio of 26.94, a price-to-earnings-growth ratio of 2.53 and a beta of 0.91. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter last year, the firm earned $1.38 EPS. The business's revenue for the quarter was up 1.4% on a year-over-year basis. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.33%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.18% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ZTS shares. Piper Sandler increased their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. UBS Group cut their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Finally, Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $180.00 to $155.00 in a report on Thursday. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $204.63.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.